SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Panacea Biotec - Quaterly Results

14 Feb 2023 Evaluate
The topline advanced to Rs. 719.70 millions, up 87.03% for the December 2022 quarter as against Rs. 384.80 millions during the year-ago period.The Total Profit for the quarter ended December 2022 of Rs. 132.40 millions grew from Rs.-224.30 millions Operating profit Margin for the quarter ended December 2022 improved to 220.00% as compared to -140.60% of corresponding quarter ended December 2021


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202212 202112 % Var 202212 202112 % Var 202203 202103 % Var
Sales 719.70 384.80 87.03 1820.50 1940.00 -6.16 2355.00 3435.60 -31.45
Other Income 97.10 23.80 307.98 241.60 100.00 141.60 125.70 207.40 -39.39
PBIDT 220.00 -140.60 -256.47 -418.90 -433.00 -3.26 -601.10 212.40 -383.00
Interest 26.80 19.10 40.31 73.60 56.00 31.43 70.40 75.20 -6.38
PBDT 193.20 -159.70 -220.98 -492.50 -489.00 0.72 -671.50 137.20 -589.43
Depreciation 60.80 64.60 -5.88 186.00 193.70 -3.98 264.30 265.70 -0.53
PBT 132.40 -224.30 -159.03 -678.50 -682.70 -0.62 -935.80 -128.50 628.25
TAX 0.00 0.00 0.00 0.00 0.00 0.00 0.00 15.60 0.00
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -7.10 0.00
PAT 132.40 -224.30 -159.03 -678.50 -682.70 -0.62 -935.80 -144.10 549.41
Equity 61.30 61.30 0.00 61.30 61.30 0.00 61.30 61.30 0.00
PBIDTM(%) 30.57 -36.54 -183.66 -23.01 -22.32 3.09 -25.52 6.18 -512.86

Panacea Biotec Share Price

358.00 5.30 (1.50%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×